Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 166-181 http://medscipublisher.com/index.php/cge 180 Kashyap D., Garg V.K., Sandberg E.N., Goel N., and Bishayee A., 2021, Oncogenic and tumor suppressive components of the cell cycle in breast cancer progression and prognosis, Pharmaceutics, 13(4): 569. https://doi.org/10.3390/pharmaceutics13040569 Kawaguchi‐Sakita N., Senda N., Inagaki-Kawata Y., Murakami H., Honda S., Yamada T., Kataoka Y., Takahara S., Tsuyuki S., Yamagami K., Moriguchi Y., Torii M., Kato T., Suwa H., Tsuji W., Suzuki E., Yamauchi A., Okamura R., Kosugi S., and Toi M., 2023, Abstract P2-05-02: potential empowerment and risk of genetic counseling with genetic breast cancer risk assessment in personalized health care: prospective cohort study using genetic counseling outcome scale (GCOS-24), Cancer Research, 83(5_Supplement): P2-05. https://doi.org/10.1158/1538-7445.SABCS22-P2-05-02 Kenemans P., Verstraeten R.A., and Verheijen R.H.M., 2004, Oncogenic pathways in hereditary and sporadic breast cancer, Maturitas, 49(1): 34-43. https://doi.org/10.1016/j.maturitas.2004.06.005 Koldehoff A., Danner M., Civello D., Rhiem K., Stock S., and Müller D., 2021, Cost-Effectiveness of targeted genetic testing for breast and ovarian cancer: a systematic review, Value in Health, 24(2): 303-312. https://doi.org/10.1016/j.jval.2020.09.016 Lee E.Y., and Muller W.J., 2010, Oncogenes and tumor suppressor genes, Cold Spring Harbor Perspectives in Biology, 2(10): a003236. https://doi.org/10.1101/cshperspect.a003236 Lee R., Sad K., Fawwal D., and Spangle J., 2023, Emerging role of epigenetic modifiers in breast cancer pathogenesis and therapeutic response, Cancers, 15(15): 4005. https://doi.org/10.3390/cancers15154005 Lehmann B., Bauer J., Chen X., Sanders M., Chakravarthy A., Shyr Y., and Pietenpol J., 2011, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, The Journal of Clinical Investigation, 121(7): 2750-2767. https://doi.org/10.1172/JCI45014 Lehmann B.D., and Pietenpol J.A., 2015, Clinical implications of molecular heterogeneity in triple negative breast cancer, The Breast, 24: S36-S40. https://doi.org/10.1016/j.breast.2015.07.009 Lima Z., Ghadamzadeh M., Arashloo F., Amjad G., Ebadi M., and Younesi L., 2019, Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms, Journal of Hematology and Oncology, 12: 1-25. https://doi.org/10.1186/s13045-019-0725-6 Llombart-Cussac A., Cortés J., Paré L., Galván P., Bermejo B., Martínez N., Vidal M., Pernas S., López R., Muñoz M., Nuciforo P., Morales S., Oliveira M., Peña L., Peláez A., and Prat A., 2017, HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial, The Lancet Oncology, 18(4): 545-554. https://doi.org/10.1016/S1470-2045(17)30021-9 Matthews E.E., 1998, Genetic testing for cancer: issues and ethical implications, Advanced Practice Nursing Quarterly, 4(2): 19-22. Mavaddat N., Antoniou A., Easton D., and García-Closas M., 2010, Genetic susceptibility to breast cancer, Molecular Oncology, 4(3): 174-191. https://doi.org/10.1016/j.molonc.2010.04.011 Maxwell K., Guidugli L., Schrader K., Hart S., Joseph V., Thomas T., Wang X., Wubbenhorst B., Klein R., Domchek S., Szabo C., Neuhausen S., Weitzel J., Nathanson K., Offit K., and Couch F., 2014, High and moderate penetrance germline mutations in a number of genes are responsible for a small proportion of familial breast cancer risk in BRCAx families, Cancer Research, 74(19_Supplement): 1291. https://doi.org/10.1158/1538-7445.AM2014-1291 Mendenhall M., Guinigundo A., Davies D., Ward P., Drosick D., and Waterhouse D., 2024, Integration of genetic testing and counseling in patients with breast cancer in a large, multisite community-based practice, JCO Oncology Practice, 20(2): 262-267. https://doi.org/10.1200/OP.22.00794 Neves N.M.B.C., Boaventura C.S., Costa M.A.F., and Bitencourt A.G.V., 2022, Ethical implications of genetic testing of susceptibility to breast cancer, Revista Bioética, 30: 636-643. https://doi.org/10.1590/1983-80422022303557es Offit K., and Thom P., 2007, Ethical and legal aspects of cancer genetic testing, Seminars in Oncology, 34(5): 435-443. https://doi.org/10.1053/j.seminoncol.2007.07.007 Osborne C., Wilson P., and Tripathy D., 2004, Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications, The Oncologist, 9(4): 361-377. https://doi.org/10.1634/theoncologist.9-4-361 Prat A., Pineda E., Adamo B., Galván P., Fernández A., Gaba L., Díez M., Viladot M., Arance A., and Muñoz M., 2015, Clinical implications of the intrinsic molecular subtypes of breast cancer, The Breast, 24: S26-S35. https://doi.org/10.1016/j.breast.2015.07.008 Schettini F., and Prat A., 2021, Dissecting the biological heterogeneity of HER2-positive breast cancer, The Breast, 59: 339-350. https://doi.org/10.1016/j.breast.2021.07.019 Schettini F., Pascual T., Conte B., Chic N., Brasó-Maristany F., Galván P., Martínez O., Adamo B., Vidal M., Muñoz M., Fernandez-Martinez A., Rognoni C., Griguolo G., Guarneri V., Conte P., Locci M., Brase J., González-Farré B., Villagrasa P., Placido S., Schiff R., Veeraraghavan J., Rimawi M., Osborne C., Pernas S., Perou C., Carey L., and Prat A., 2020, HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis, Cancer Treatment Reviews, 84: 101965. https://doi.org/10.1016/j.ctrv.2020.101965
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==